血浆NfL作为早期帕金森病疲劳诊断和预后生物标志物的潜在用途

IF 4.7 2区 医学 Q1 CLINICAL NEUROLOGY
Therapeutic Advances in Neurological Disorders Pub Date : 2025-03-17 eCollection Date: 2025-01-01 DOI:10.1177/17562864251324406
Ningning Che, Jingxuan Huang, Shichan Wang, Qirui Jiang, Tianmi Yang, Yi Xiao, Junyu Lin, Jiajia Fu, Ruwei Ou, Chunyu Li, Xueping Chen, Huifang Shang
{"title":"血浆NfL作为早期帕金森病疲劳诊断和预后生物标志物的潜在用途","authors":"Ningning Che, Jingxuan Huang, Shichan Wang, Qirui Jiang, Tianmi Yang, Yi Xiao, Junyu Lin, Jiajia Fu, Ruwei Ou, Chunyu Li, Xueping Chen, Huifang Shang","doi":"10.1177/17562864251324406","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Fatigue is a prevalent non-motor symptom that often appears in the early stages of Parkinson's disease (PD). Plasma neurofilament light chain (NfL) was elevated in PD patients and may be considered a potential biomarker for both motor and cognitive progression.</p><p><strong>Objectives: </strong>In this study, we explored the association between plasma NfL levels and various fatigue subtypes and the prediction of baseline plasma NfL levels for fatigue subtype conversion.</p><p><strong>Methods: </strong>Patients with PD were classified into four categories: persistent fatigue, never fatigue, non-persistent fatigue, and new-onset fatigue. They underwent detailed neurological evaluations at baseline and a 2-year follow-up. Plasma NfL, glial fibrillary acidic protein, phosphorylated tau181, amyloid beta 42, and Aβ40 levels in both PD patients and control subjects were measured using an ultrasensitive single molecule array.</p><p><strong>Results: </strong>The study enrolled 174 PD patients and 95 control subjects. Plasma NfL levels were significantly higher in the persistent fatigue group compared to the never fatigue group at the 2-year follow-up (<i>p</i> <i><</i> 0.05). Longitudinally, 45.16% of baseline fatigue patients converted to non-fatigue at the 2-year follow-up. Additionally, 22.12% of patients initially without-figure patients converted to fatigue patients at the 2-year follow-up. Baseline plasma NfL levels were significantly higher in both the persistent fatigue and new-onset fatigue groups compared to the never fatigue group (<i>p</i> <i><</i> 0.05). Higher baseline NfL levels were significantly associated with new-onset fatigue (odds ratio = 1.127, <i>p</i> = 0.034) after adjusting for confounders.</p><p><strong>Conclusion: </strong>Baseline plasma NfL levels may serve as a biomarker for predicting fatigue subtype conversion and the progression of fatigue in PD.</p>","PeriodicalId":22980,"journal":{"name":"Therapeutic Advances in Neurological Disorders","volume":"18 ","pages":"17562864251324406"},"PeriodicalIF":4.7000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912176/pdf/","citationCount":"0","resultStr":"{\"title\":\"The potential use of plasma NfL as a diagnostic and prognostic biomarker of fatigue in early Parkinson's disease.\",\"authors\":\"Ningning Che, Jingxuan Huang, Shichan Wang, Qirui Jiang, Tianmi Yang, Yi Xiao, Junyu Lin, Jiajia Fu, Ruwei Ou, Chunyu Li, Xueping Chen, Huifang Shang\",\"doi\":\"10.1177/17562864251324406\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Fatigue is a prevalent non-motor symptom that often appears in the early stages of Parkinson's disease (PD). Plasma neurofilament light chain (NfL) was elevated in PD patients and may be considered a potential biomarker for both motor and cognitive progression.</p><p><strong>Objectives: </strong>In this study, we explored the association between plasma NfL levels and various fatigue subtypes and the prediction of baseline plasma NfL levels for fatigue subtype conversion.</p><p><strong>Methods: </strong>Patients with PD were classified into four categories: persistent fatigue, never fatigue, non-persistent fatigue, and new-onset fatigue. They underwent detailed neurological evaluations at baseline and a 2-year follow-up. Plasma NfL, glial fibrillary acidic protein, phosphorylated tau181, amyloid beta 42, and Aβ40 levels in both PD patients and control subjects were measured using an ultrasensitive single molecule array.</p><p><strong>Results: </strong>The study enrolled 174 PD patients and 95 control subjects. Plasma NfL levels were significantly higher in the persistent fatigue group compared to the never fatigue group at the 2-year follow-up (<i>p</i> <i><</i> 0.05). Longitudinally, 45.16% of baseline fatigue patients converted to non-fatigue at the 2-year follow-up. Additionally, 22.12% of patients initially without-figure patients converted to fatigue patients at the 2-year follow-up. Baseline plasma NfL levels were significantly higher in both the persistent fatigue and new-onset fatigue groups compared to the never fatigue group (<i>p</i> <i><</i> 0.05). Higher baseline NfL levels were significantly associated with new-onset fatigue (odds ratio = 1.127, <i>p</i> = 0.034) after adjusting for confounders.</p><p><strong>Conclusion: </strong>Baseline plasma NfL levels may serve as a biomarker for predicting fatigue subtype conversion and the progression of fatigue in PD.</p>\",\"PeriodicalId\":22980,\"journal\":{\"name\":\"Therapeutic Advances in Neurological Disorders\",\"volume\":\"18 \",\"pages\":\"17562864251324406\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-03-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912176/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Neurological Disorders\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/17562864251324406\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Neurological Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562864251324406","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:疲劳是帕金森病(PD)早期常见的非运动症状。血浆神经丝轻链(NfL)在PD患者中升高,可能被认为是运动和认知进展的潜在生物标志物。目的:在本研究中,我们探讨血浆NfL水平与各种疲劳亚型之间的关系,以及预测疲劳亚型转化的基线血浆NfL水平。方法:将PD患者分为持续性疲劳、从不疲劳、非持续性疲劳和新发疲劳4类。他们在基线时接受了详细的神经学评估和2年的随访。采用超灵敏单分子阵列检测PD患者和对照组血浆NfL、胶质原纤维酸性蛋白、磷酸化tau181、淀粉样蛋白β 42和Aβ40水平。结果:本研究纳入174例PD患者和95例对照组。2年随访时,持续疲劳组血浆NfL水平明显高于非疲劳组(p < 0.05)。纵向上,45.16%的基线疲劳患者在2年随访时转为无疲劳。此外,在2年的随访中,22.12%的患者从最初的无数字患者转变为疲劳患者。与非疲劳组相比,持续性疲劳组和新发疲劳组的基线血浆NfL水平均显著升高(p < 0.05)。调整混杂因素后,较高的基线NfL水平与新发疲劳显著相关(优势比= 1.127,p = 0.034)。结论:血浆NfL基线水平可作为预测PD患者疲劳亚型转化和疲劳进展的生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The potential use of plasma NfL as a diagnostic and prognostic biomarker of fatigue in early Parkinson's disease.

Background: Fatigue is a prevalent non-motor symptom that often appears in the early stages of Parkinson's disease (PD). Plasma neurofilament light chain (NfL) was elevated in PD patients and may be considered a potential biomarker for both motor and cognitive progression.

Objectives: In this study, we explored the association between plasma NfL levels and various fatigue subtypes and the prediction of baseline plasma NfL levels for fatigue subtype conversion.

Methods: Patients with PD were classified into four categories: persistent fatigue, never fatigue, non-persistent fatigue, and new-onset fatigue. They underwent detailed neurological evaluations at baseline and a 2-year follow-up. Plasma NfL, glial fibrillary acidic protein, phosphorylated tau181, amyloid beta 42, and Aβ40 levels in both PD patients and control subjects were measured using an ultrasensitive single molecule array.

Results: The study enrolled 174 PD patients and 95 control subjects. Plasma NfL levels were significantly higher in the persistent fatigue group compared to the never fatigue group at the 2-year follow-up (p< 0.05). Longitudinally, 45.16% of baseline fatigue patients converted to non-fatigue at the 2-year follow-up. Additionally, 22.12% of patients initially without-figure patients converted to fatigue patients at the 2-year follow-up. Baseline plasma NfL levels were significantly higher in both the persistent fatigue and new-onset fatigue groups compared to the never fatigue group (p< 0.05). Higher baseline NfL levels were significantly associated with new-onset fatigue (odds ratio = 1.127, p = 0.034) after adjusting for confounders.

Conclusion: Baseline plasma NfL levels may serve as a biomarker for predicting fatigue subtype conversion and the progression of fatigue in PD.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
8.30
自引率
1.70%
发文量
62
审稿时长
15 weeks
期刊介绍: Therapeutic Advances in Neurological Disorders is a peer-reviewed, open access journal delivering the highest quality articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of neurology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in neurology, providing a forum in print and online for publishing the highest quality articles in this area.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信